CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Inclusion Criteria20

• , age 3-18 years old (including boundary value), male and female;
• \. The patient was clinically diagnosed as relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoblastic
• Patients with tumors who meet one of the following conditions:
• • Complete marrow response (MRD\>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy
• Complete response at the molecular level and immunology (characterized by specific molecular markers and immunophenotypes prior to treatment)
• Patients, did not turn negative after treatment);
• Recurrence during chemotherapy, early recurrence after drug withdrawal (\<12 months) or late recurrence after complete remission (≥
• months) and did not achieve complete remission after 1 course of standard induction regimen (MRD\>1%);
• Recurrence after bone marrow transplantation;
• Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined
• recrudescence
• \. Lansky score ≥60;
• , the treatment related antigen test result is positive (CD19/CD20/CD22);
• \. The expected survival period from the signing date of the informed consent is more than 3 months;
• , HGB≥70g/L (blood transfusion);
• , liver and kidney function, cardiopulmonary function meet the following requirements:
• Creatinine ≤1.5×ULN;
• Left ventricular ejection fraction ≥50%;
• Blood oxygen saturation \>90%;
• Total bilirubin ≤1.5×ULN; ALT and AST≤2.5 x ULN.-